Skip to main content
padlock icon - secure page this page is secure

Safety of rituximab therapy during the first trimester of pregnancy: a case history

Buy Article:

$52.00 + tax (Refund Policy)

Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history.

Eur J Haematol 2004: 72: 292–295. © Blackwell Munksgaard 2004. Abstract:

The optimal treatment of non-Hodgkin's lymphoma (NHL) during pregnancy is currently undefined. The potential teratogenic effects of conventional chemotherapy preclude its use during the first trimester of pregnancy. We report the case of a pregnant woman with relapsed indolent follicular NHL who was treated with rituximab (unintentionally) during the first trimester. The treatment stabilised the disease. Following an uncomplicated pregnancy, a healthy child was born at full term and careful haematological and immunological monitoring has revealed no adverse effects resulting from exposure to rituximab. Data of using rituximab during pregnancy are scarce, but the present case shows that rituximab may be one option for treatment of NHL in early pregnancy.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: first trimester; follicular lymphoma; pregnancy; rituximab; safety

Document Type: Research Article

Affiliations: 1: Department of Medicine, Division of Hematology 2: Department of Oncology 3: Department of Pediatrics, Karolinska Institutet at Huddinge University Hospital and South Hospital, Stockholm, Sweden

Publication date: April 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more